| Prognosis of COVID-19: Changes in laboratory parameters M Lagadinou, EE Solomou, N Zareifopoulos, M Marangos, C Gogos, ... Age (yrs) 62 (13.4), 47-16.42, 2020 | 79 | 2020 |
| Neuropsychiatric effects of antimicrobial agents N Zareifopoulos, G Panayiotakopoulos Clinical drug investigation 37, 423-437, 2017 | 62 | 2017 |
| Prevalence, contribution to disease burden and management of comorbid depression and anxiety in chronic obstructive pulmonary disease: a narrative review N Zareifopoulos, A Bellou, A Spiropoulou, K Spiropoulos COPD: Journal of Chronic Obstructive Pulmonary Disease 16 (5-6), 406-417, 2019 | 42 | 2019 |
| Prevalence of comorbid chronic obstructive pulmonary disease in individuals suffering from schizophrenia and bipolar disorder: a systematic review N Zareifopoulos, A Bellou, A Spiropoulou, K Spiropoulos COPD: Journal of Chronic Obstructive Pulmonary Disease 15 (6), 612-620, 2018 | 42 | 2018 |
| Presepsin as a diagnostic and prognostic biomarker in sepsis D Velissaris, N Zareifopoulos, V Karamouzos, E Karanikolas, C Pierrakos, ... Cureus 13 (5), 2021 | 38 | 2021 |
| Intubation and mechanical ventilation of patients with COVID-19: what should we tell them? N Zareifopoulos, M Lagadinou, A Karela, G Karantzogiannis, D Velissaris Monaldi Archives for Chest Disease 90 (1), 2020 | 36 | 2020 |
| Atrial fibrillation is associated with cognitive impairment, all-cause dementia, vascular dementia, and Alzheimer’s disease: a systematic review and meta-analysis CA Papanastasiou, CA Theochari, N Zareifopoulos, A Arfaras-Melainis, ... Journal of General Internal Medicine 36, 3122-3135, 2021 | 32 | 2021 |
| Effects of 5-HT-7 receptor ligands on memory and cognition N Zareifopoulos, C Papatheodoropoulos Neurobiology of learning and memory 136, 204-209, 2016 | 32 | 2016 |
| Review of the association between periodontitis and chronic obstructive pulmonary disease in smokers A Spiropoulou, N Zareifopoulos, A Bellou, K Spiropoulos, L Tsalikis Monaldi Archives for Chest Disease 89 (1), 2019 | 24 | 2019 |
| Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: a meta-analysis N Zareifopoulos, I Dylja Asian journal of psychiatry 26, 115-122, 2017 | 24 | 2017 |
| Procalcitonin and sepsis in the Emergency Department: an update. D Velissaris, N Zareifopoulos, M Lagadinou, C Platanaki, K Tsiotsios, ... European Review for Medical & Pharmacological Sciences 25 (1), 2021 | 20 | 2021 |
| Treatment options for acute agitation in psychiatric patients: theoretical and empirical evidence N Zareifopoulos, G Panayiotakopoulos Cureus 11 (11), 2019 | 20 | 2019 |
| Association between atrial fibrillation and cognitive impairment in individuals with prior stroke: a meta-analysis and meta-regression analysis DG Kokkinidis, N Zareifopoulos, CA Theochari, A Arfaras-Melainis, ... Stroke 51 (6), 1662-1666, 2020 | 19 | 2020 |
| Neuropsychiatric effects of antiviral drugs N Zareifopoulos, M Lagadinou, A Karela, O Kyriakopoulou, D Velissaris Cureus 12 (8), 2020 | 16 | 2020 |
| Alterations in lymphocyte subsets and monocytes in patients diagnosed with SARS-CoV-2 pneumonia: a mini review of the literature. M Lagadinou, N Zareifopoulos, D Gkentzi, F Sampsonas, E Kostopoulou, ... European Review for Medical & Pharmacological Sciences 25 (15), 2021 | 15 | 2021 |
| Management of COVID-19: the risks associated with treatment are clear, but the benefits remain uncertain N Zareifopoulos, M Lagadinou, A Karela, C Platanaki, G Karantzogiannis, ... Monaldi Archives for Chest Disease 90 (2), 2020 | 13 | 2020 |
| Soluble urokinase plasminogen activator receptor as a diagnostic and prognostic biomarker in cardiac disease D Velissaris, N Zareifopoulos, I Koniari, V Karamouzos, D Bousis, ... Journal of clinical medicine research 13 (3), 133, 2021 | 12 | 2021 |
| Are patients with autoimmune disease at greater risk of developing severe COVID-19? M Lagadinou, N Zareifopoulos, A Karela, O Kyriakopoulou, D Velissaris Journal of Clinical Medicine Research 12 (8), 539, 2020 | 6 | 2020 |
| Pathophysiology and management of Akathisia 70 years after the introduction of the chlorpromazine, the first antipsychotic. N Zareifopoulos, M Katsaraki, P Stratos, V Villiotou, M Skaltsa, A Dimitriou, ... European Review for Medical & Pharmacological Sciences 25 (14), 2021 | 5 | 2021 |
| Efavirenz as a psychotropic drug. N Zareifopoulos, M Lagadinou, A Karela, F Pouliasi, I Economou, ... European Review for Medical & Pharmacological Sciences 24 (20), 2020 | 5 | 2020 |
